SCHEMBL340511

SCHEMBL340511

O=C(O)c1cc(I)cc(I)c1O.[LiH]

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.54
ERN1 O75460 1/20 0.45
MAOB P27338 1/20 0.43
TP53 P04637 1/20 0.43
AKR1C4 P17516 2/20 0.41
AKR1C3 P42330 2/20 0.41
AKR1C2 P52895 2/20 0.41
AKR1C1 Q04828 2/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 2/20 0.39
PDE4A P27815 1/20 0.39
BLVRB P30043 1/20 0.39
KDR P35968 1/20 0.39
HPGD P15428 4/20 0.38
HSD17B10 Q99714 3/20 0.38
THRB P10828 2/20 0.38
ALOX12 P18054 2/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29396210 0.98 TTR (0.56) TTRERN1MAOBTP53AKR1C4
SCHEMBL425350 0.98 TTR (0.56) TTRERN1MAOBTP53AKR1C4
Lithium SCHEMBL410866 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
SCHEMBL9398438 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
SCHEMBL27960207 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
SCHEMBL23803707 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
Lithium SCHEMBL30311136 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
SCHEMBL9403722 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
SCHEMBL27658640 0.96 TTR (0.54) TTRERN1MAOBTP53AKR1C4
Water SCHEMBL9398918 0.94 TTR (0.52) TTRERN1MAOBTP53AKR1C4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117822128-A Single-cell whole genome library and combined indexing method for preparing same 俄勒冈健康与科学大学 2024-04-05 CN claimed
CN-101918212-B There is the transparent multilayer sheet of electrostatic dissipative properties LUBRIZOL ADVANCED MATERIALS, INC. (US) 2016-04-27 CN claimed
US-8808843-B2 Transparent multilayer sheet having electrostatic dissipative properties LUBRIZOL ADVANCED MATERIALS, INC. (US) 2014-08-19 US claimed
US-20120021198-A1 Transparent Multilayer Sheet Having Electrostatic Dissipative Properties LUBRIZOL ADVANCED MATERIALS, INC. (US) 2012-01-26 US claimed
CN-101918212-A Transparent multilayer sheet having electrostatic dissipative properties LUBRIZOL ADVANCED MAT INC 2010-12-15 CN claimed
EP-2227391-A1 TRANSPARENT MULTILAYER SHEET HAVING ELECTROSTATIC DISSIPATIVE PROPERTIES Lubrizol Advanced Materials, Inc. (US) 2010-09-15 EP claimed
WO-2009086246-A1 TRANSPARENT MULTILAYER SHEET HAVING ELECTROSTATIC DISSIPATIVE PROPERTIES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2009-07-09 WO claimed
WO-2008018776-A1 ELECTROSTATIC DISSIPATIVE POLYMER AND POLYMER MIXTURE THEREOF SK CHEMICALS CO., LTD. (KR) 2008-02-14 WO claimed
WO-1993003375-A1 AUTOANTIBODIES AND THEIR TARGETS IN THE DIAGNOSIS OF PERIPHERAL NEUROPATHIES WASHINGTON UNIVERSITY (US) 1993-02-18 WO claimed
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels THE CLEVELAND CLINIC FOUNDATION (US) 2026-03-17 US disclosed
US-20250283819-A1 RAPID PATHOLOGY/CYTOLOGY WITHOUT WASH ESSENLIX CORPORATION (US) 2025-09-11 US disclosed
US-12405216-B2 Rapid pathology/cytology without wash ESSENLIX CORPORATION (US) 2025-09-02 US disclosed
US-20250249453-A1 SYSTEMS AND METHODS FOR SERIAL FLOW EMULSION PROCESSES DROPWORKS, INC. 2025-08-07 US disclosed
US-12364981-B2 Systems and methods for serial flow emulsion processes DROPWORKS, INC. (US) 2025-07-22 US disclosed
EP-0437800-A1 Derivatives and analogues of monoethylglycinexylidide and their production and use ABBOTT LABORATORIES (US) 1991-07-24 EP disclosed
US-4859464-A SOLUBILIZATION WITH NONIONIC DETERGENT ANTONIO LAWRENCE E (US) 1989-08-22 US disclosed
EP-0101505-B1 METHOD FOR THE PURIFICATION OF PARASITE ANTIGENIC FACTORS D'ANTONIO, Lawrence E. (US) 1987-11-04 EP disclosed
EP-0101505-A4 METHOD FOR THE PURIFICATION OF PARASITE ANTIGENIC FACTORS. D ANTONIO LAWRENCE E 1984-07-06 EP disclosed
EP-0101505-A1 METHOD FOR THE PURIFICATION OF PARASITE ANTIGENIC FACTORS. ANTONIO LAWRENCE E 1984-02-29 EP disclosed
WO-1983002896-A1 METHOD FOR THE PURIFICATION OF PARASITE ANTIGENIC FACTORS D'ANTONIO, LAWRENCE, E. 1983-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12576055-B2 Disease detection and treatment based on trimethyl-lysine levels BHMT, BHMT2, EHMT2 TTR 386/4885ERN1 2851/4885MAOB 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.